Different gut microbial communities correlate with efficacy of albendazole-ivermectin against soil-transmitted helminthiases

Pierre H H Schneeberger, Morgan Gueuning, Sophie Welsche, Eveline Hürlimann, Julian Dommann, Cécile Häberli, Jürg E Frey, Somphou Sayasone, Jennifer Keiser, Pierre H H Schneeberger, Morgan Gueuning, Sophie Welsche, Eveline Hürlimann, Julian Dommann, Cécile Häberli, Jürg E Frey, Somphou Sayasone, Jennifer Keiser

Abstract

Soil-transmitted helminth infections represent a large burden with over a quarter of the world's population at risk. Low cure rates are observed with standard of care (albendazole); therefore, a more effective combination therapy (albendazole and ivermectin) is being investigated but showed variable treatment efficacies without evidence of intrinsic parasite resistance. Here, we analyzed the microbiome of Trichuris trichiura and hookworm-infected patients and found an association of different enterotypes with treatment efficacy. 80 T. trichiura-infected patients with hookworm co-infections from Pak-Khan, Laos, received either albendazole (n = 41) or albendazole and ivermectin combination therapy (n = 39). Pre-/post-treatment stool samples were collected to monitor treatment efficacy and microbial communities were profiled using 16S rRNA gene sequencing, qPCR, and shotgun sequencing. We identified three bacterial enterotypes and show that pre-treatment enterotype is associated with efficacy of the combination treatment for both T. trichiura (CRET1 = 5.8%; CRET2 = 16.6%; CRET3 = 68.8%) and hookworm (CRET1 = 31.3%; CRET2 = 16.6%; CRET3 = 78.6%). This study shows that pre-treatment enterotype enables predicting treatment outcome of combination therapy for T. trichiura and hookworm infections.Trial registration: ClinicalTrials.gov, NCT03527732. Registered 17 May 2018, https://ichgcp.net/clinical-trials-registry/NCT03527732 .

Conflict of interest statement

The authors declare no competing interests.

© 2022. The Author(s).

Figures

Fig. 1. Trial profile.
Fig. 1. Trial profile.
Trial profile depicting the number of patients included for microbiome analyses.
Fig. 2. Underlying compositional structures and their…
Fig. 2. Underlying compositional structures and their taxonomic features.
A Gut microbial community composition of patients infected with Trichuris trichiura before treatment. The cladogram was generated using Bray–Curtis dissimilarity. B Performance of classification in this dataset using a random forest model. Taxonomic features are ranked according to their individual contribution to sample classification. C Bacterial genera found to be enriched in one of the enterotype using a Kruskal–Wallis test for group comparison combined with a linear discriminant analysis for effect size (Lefse). D Non-metric multidimensional scaling ordination plot of baseline samples using Bray–Curtis dissimilarity. The labeled genera were found to be enriched in either enterotype. Treatment arm A = albendazole and ivermectin, treatment arm B = albendazole, ET enterotype.
Fig. 3. Taxon-specific and total bacterial qPCR…
Fig. 3. Taxon-specific and total bacterial qPCR to classify pre-treatment sample in a treatment-relevant category.
A Total bacteria and taxon-specific density measured by quantitative PCR (qPCR), by enterotype. Comparison of absolute abundances between enterotype 1 (n = 17), enterotype 2 (n = 6), and enterotype 3 (n = 16) was conducted using two-sided Mann-Whitney tests. The lower and upper bound of each box represent the 25th and 75th percentiles, respectively, and the line within indicates the median. The whiskers represent the minimum and maximum values. B Classification sensitivity and specificity into the enterotype using qPCR values. PREV Prevotella genus qPCR target, FAEC Faecalibacterium genus qPCR target, ESCH Escherichia coli qPCR target; 16S total bacteria qPCR target.
Fig. 4. Association between soil-transmitted helminths cure…
Fig. 4. Association between soil-transmitted helminths cure and pre-treatment enterotype (ET) by treatment arm and species-level characteristics of each enterotype.
A Association between treatment outcome of Trichuris trichiura and ET at baseline. B Association measured between treatment outcome of hookworm and ET before treatment. The cure rate is defined as the presence or absence of eggs in stool between day 14 and day 28 after treatment (= average eggs per gram of stool in samples collected between days 14 and 28 after treatment). C Species-level differences between compositional clusters (= enterotypes). Fisher’s exact tests were two-sided and the 95% confidence interval of the odds ratios is shown in the bracket. Labels on the pie charts represent the number of patients in each group. n number of patients, OR odds ratios.
Fig. 5. Relationship between pre-treatment enterotype and…
Fig. 5. Relationship between pre-treatment enterotype and daily post-treatment egg counts of Trichuris trichiura and hookworm.
A Kaplan–Meier curve showing the remaining proportion of infected patients over time, stratified by baseline enterotype. T. trichiura cure is shown on the left, while hookworm cure is shown on the right. B Averaged daily egg counts of T. trichiura (upper two panels) and hookworm (lower two panels) stratified by pre-treatment enterotype. Daily egg counts are shown for the combination therapy (albendazole and ivermectin; left half panels) and monotherapy (albendazole; right half panels). The black dashed lines indicate the lower and upper thresholds of moderate infections for each parasite. ND not detected, post-tx post-treatment, ALB albendazole, IVE ivermectin.
Fig. 6. Comparison of metabolic potential between…
Fig. 6. Comparison of metabolic potential between enterotypes.
A Venn diagram showing qualitative overlap of KEGG orthology terms (KO) between treatment-relevant enterotypes. B Volcano plots highlight quantitative differences (differences in normalized counts) at the KO level between enterotypes. The comparison was performed using Deseq2 and P-values were adjusted for multiple testing bias using the Benjamini–Hochberg procedure. C Principal component analysis to display community-level differences of KO. A PERMANOVA analysis was conducted to quantify these differences. D Bar chart showing the average relative abundances of high-level KEGG pathways, by enterotype. For clarity, only proportions of sequences above 2% are shown. E Comparison between enterotypes of relative abundances of metabolic pathways associated with positive soil-transmitted helminth infection status in previous studies–. A Kruskal–Wallis test was used in combination with the Benjamini–Hochberg multiple testing bias corrections to identify differences and fold changes were calculated to show the corresponding effect sizes. ET1–3 enterotypes 1–3, FC fold change, Ref. Reference.

References

    1. Jourdan PM, Lamberton PHL, Fenwick A, Addiss DG. Soil-transmitted helminth infections. Lancet. 2018;391:252–265.
    1. Keiser J, Utzinger J. Community-wide soil-transmitted helminth treatment is equity-effective. Lancet. 2019;393:2011–2012.
    1. Palmeirim MS, Ame SM, Ali SM, Hattendorf J, Keiser J. Efficacy and safety of a single dose versus a multiple dose regimen of mebendazole against hookworm infections in children: a randomised, double-blind. Trial EClinicalMedicine. 2018;1:7–13.
    1. Keiser J, Utzinger J. Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis. J. Am. Med. Assoc. 2008;299:1937–1948.
    1. Moser, W., Schindler, C. & Keiser, J. Efficacy of recommended drugs against soil transmitted helminths: systematic review and network meta-analysis. BMJ358, j4307 (2017).
    1. World Health Organization. Guideline: preventive chemotherapy to control soil-transmitted helminth infections in at-risk population groups (2017).
    1. Palmeirim, M. S. et al. Preclinical and clinical characteristics of the trichuricidal drug oxantel pamoate and clinical development plans: a review. Drugs. 81, 907–921 (2021).
    1. Hotez PJ, et al. Eliminating the neglected tropical diseases: translational science and new technologies. PLoS Negl. Trop. Dis. 2016;10:e0003895.
    1. Moser W, Schindler C, Keiser J. Drug combinations against soil-transmitted helminth infections. Adv. Parasitol. 2019;103:91–115.
    1. Omura, S. The Search for Bioactive Compounds from Microorganisms. (Springer Science & Business Media, 1992).
    1. Knopp S, et al. Albendazole and mebendazole administered alone or in combination with ivermectin against Trichuris trichiura: a randomized controlled trial. Clin. Infect. Dis. 2010;51:1420–1428.
    1. Hürlimann, E. et al. Efficacy and safety of co-administered ivermectin and albendazole in school-aged children and adults infected with Trichuris trichiura in Côte d'Ivoire, Laos, and Pemba Island, Tanzania: a double-blind, parallel-group, phase 3, randomised controlled trial. Lancet Infect. Dis.22, 123–135 (2022).
    1. Spanogiannopoulos P, Bess EN, Carmody RN, Turnbaugh PJ. The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism. Nat. Rev. Microbiol. 2016;14:273.
    1. Ananthakrishnan AN, et al. Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases. Cell Host Microbe. 2017;21:603–610. e603.
    1. Routy B, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91–97.
    1. Schneeberger PHH, et al. Investigations on the interplays between Schistosoma mansoni, praziquantel and the gut microbiome. Parasites Vectors. 2018;11:168.
    1. Schneeberger PHH, et al. Off-target effects of tribendimidine, tribendimidine plus ivermectin, tribendimidine plus oxantel-pamoate, and albendazole plus oxantel-pamoate on the human gut microbiota. Int. J. Parasitol. 2018;8:372–378.
    1. Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman AL. Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019;570:462–467.
    1. Zhang J, Zhang J, Wang R. Gut microbiota modulates drug pharmacokinetics. Drug Metab. Rev. 2018;50:357–368.
    1. Alexander JL, et al. Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat. Rev. Gastroenterol. Hepatol. 2017;14:356–365.
    1. Keller L, et al. Long-term outcomes of ivermectin-albendazole versus albendazole alone against soil-transmitted helminths: results from randomized controlled trials in Lao PDR and Pemba Island, Tanzania. PLoS Negl. Trop. Dis. 2021;15:e0009561.
    1. Rubel MA, et al. Lifestyle and the presence of helminths is associated with gut microbiome composition in Cameroonians. Genome Biol. 2020;21:122.
    1. Rosa BA, et al. Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia. Microbiome. 2018;6:33.
    1. Lee SC, et al. Helminth colonization is associated with increased diversity of the gut microbiota. PLoS Negl. Trop. Dis. 2014;8:e2880.
    1. Cardwell LA, Alinia H, Tuchayi SM, Feldman SR. New developments in the treatment of rosacea—role of once-daily ivermectin cream. Clin. Cosmet. Investig. Dermatol. 2016;9:71.
    1. Juarez M, Schcolnik-Cabrera A, Dueñas-Gonzalez A. The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug. Am. J. Cancer Res. 2018;8:317.
    1. Janas A, Przybylski P. 14-and 15-membered lactone macrolides and their analogues and hybrids: structure, molecular mechanism of action and biological activity. Eur. J. Med. Chem. 2019;182:111662.
    1. Klugman K, Capper T, Widdowson C, Koornhof H, Moser W. Increased activity of 16-membered lactone ring macrolides against erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae: characterization of South African isolates. J. Antimicrob. Chemother. 1998;42:729–734.
    1. Arsic B, et al. 16-membered macrolide antibiotics: a review. Int. J. Antimicrob. Agents. 2018;51:283–298.
    1. Doan T, et al. Gut microbiome alteration in MORDOR I: a community-randomized trial of mass azithromycin distribution. Nat. Med. 2019;25:1370–1376.
    1. Klünemann, M. et al. Bioaccumulation of therapeutic drugs by human gut bacteria. Nature597, 533–538 (2021).
    1. Patel C, et al. Efficacy and safety of ivermectin and albendazole co-administration in school-aged children and adults infected with Trichuris trichiura: study protocol for a multi-country randomized controlled double-blind trial. BMC Infect. Dis. 2019;19:1–10.
    1. Kaisar MM, et al. Improved diagnosis of Trichuris trichiura by using a bead-beating procedure on ethanol preserved stool samples prior to DNA isolation and the performance of multiplex real-time PCR for intestinal parasites. Parasitology. 2017;144:965–974.
    1. Keller L, et al. Performance of the Kato-Katz method and real time polymerase chain reaction for the diagnosis of soil-transmitted helminthiasis in the framework of a randomised controlled trial: treatment efficacy and day-to-day variation. Parasites Vectors. 2020;13:1–12.
    1. Schneeberger PHH, et al. Microbiota analysis optimization for human bronchoalveolar lavage fluid. Microbiome. 2019;7:1–16.
    1. Cho Matthew Y, et al. Two-target quantitative PCR to predict library composition for shallow shotgun sequencing. mSystems. 2021;6:e00552–00521.
    1. Bolyen E, et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat. Biotechnol. 2019;37:852–857.
    1. Quast C, et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res. 2012;41:D590–D596.
    1. McDonald, D. et al. The Biological Observation Matrix (BIOM) format or: how I learned to stop worrying and love the ome-ome. Gigascience110.1186/2047-217X-1-7 (2012).
    1. Beghini F, et al. Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3. eLife. 2021;10:e65088.
    1. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat. Methods. 2012;9:357–359.
    1. Aitchison J. The statistical analysis of compositional data. J. R. Stat. Soc. 1982;44:139–160.
    1. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:1–21.
    1. Benjamini Y, Hochberg Y. Controlling the false discovery rate—a practical and powerful approach to multiple testing. J. R. Stat. Soc. B Methods. 1995;57:289–300.
    1. Nadkarni MA, Martin FE, Jacques NA, Hunter N. Determination of bacterial load by real-time PCR using a broad-range (universal) probe and primers set. Microbiology. 2002;148:257–266.
    1. Martin FE, Nadkarni MA, Jacques NA, Hunter N. Quantitative microbiological study of human carious dentine by culture and real-time PCR: association of anaerobes with histopathological changes in chronic pulpitis. J. Clin. Microbiol. 2002;40:1698–1704.
    1. Lopez-Siles M, et al. Mucosa-associated Faecalibacterium prausnitzii and Escherichia coli co-abundance can distinguish irritable bowel syndrome and inflammatory bowel disease phenotypes. Int. J. Med. Microbiol. 2014;304:464–475.
    1. Huijsdens XW, et al. Quantification of bacteria adherent to gastrointestinal mucosa by real-time PCR. J. Clin. Microbiol. 2002;40:4423–4427.
    1. Team, R. C. R: A language and environment for statistical computing. (2013).
    1. Oksanen J, et al. The vegan package. Commun. Ecol. Package. 2007;10:719.
    1. Murtagh F, Legendre P. Ward’s hierarchical agglomerative clustering method: which algorithms implement ward’s criterion? J. Classification. 2014;31:274–295.
    1. Breiman L. Random Forests. Mach. Learn. 2001;45:5–32.
    1. Robin X, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinforma. 2011;12:77.
    1. Segata N, et al. Metagenomic biomarker discovery and explanation. Genome Biol. 2011;12:R60–R60.
    1. Andersen PK, Gill RD. Cox’s regression model for counting processes: a large sample study. Ann. Stat. 1982;10:1100–1120.
    1. Chong J, Liu P, Zhou G, Xia J. Using MicrobiomeAnalyst for comprehensive statistical, functional, and meta-analysis of microbiome data. Nat. Protoc. 2020;15:799–821.
    1. Foster ZSL, Sharpton TJ, Grünwald NJ. Metacoder: an R package for visualization and manipulation of community taxonomic diversity data. PLOS Comput. Biol. 2017;13:e1005404.

Source: PubMed

3
订阅